Agree Realty's Impact: BioDlink Launches China’s First EGFR-Targeting ADC, MEIYOUHENG®
- BioDlink, in partnership with Lepu Biopharma, launched MEIYOUHENG®, China's first EGFR-targeting ADC, on November 20, 2025.
- The collaboration highlights BioDlink's operational excellence and strengthens its reputation in biologics manufacturing.
- MEIYOUHENG®'s success showcases the potential for CDMOs to drive innovation and develop advanced manufacturing capabilities in biopharmaceuticals.
Pioneering Developments in Biologics Manufacturing: BioDlink's Breakthrough with MEIYOUHENG®
In a significant advancement for the biopharmaceutical industry, BioDlink, a leading biologics contract development and manufacturing organization (CDMO), along with its partner Lepu Biopharma, successfully launches MEIYOUHENG® (Becotatug Vedotin injection), the first EGFR-targeting antibody-drug conjugate (ADC) to enter the Chinese market. This milestone, celebrated on November 20, 2025, not only marks the inaugural ADC fully manufactured by a CDMO in China but also showcases the region's growing capabilities in biopharmaceutical innovation. The launch is particularly noteworthy as it demonstrates the potential of CDMOs to lead in the development and production of complex biologics.
The collaboration between BioDlink and Lepu Biopharma has spanned over two years and is characterized by efficient technology transfer and robust GMP manufacturing practices. BioDlink achieves a remarkable timeline, completing the technology transfer in less than three months and the production process in under eleven months, all while adhering to stringent quality systems and regulatory standards. The approval from China’s National Medical Products Administration (NMPA) on October 30, 2025, underscores the effectiveness of BioDlink's comprehensive support during the pre-Approval Inspection (PAI) preparation and Biologics License Application (BLA) processes. This achievement not only reflects BioDlink's operational excellence but also enhances its reputation as a leader in the biologics manufacturing sector.
Dr. Jian Zhang, COO of BioDlink, expresses pride in the partnership’s success, highlighting the breakthrough nature of this development for the industry. He emphasizes that the collaboration with Lepu Biopharma has been pivotal in navigating the complexities associated with bringing a novel ADC to market. Meanwhile, Dr. Ziye Sui, CEO of Lepu Biopharma, recognizes BioDlink as a strategic partner, moving beyond the role of a mere service provider. This collaborative approach illustrates the growing trend within the biopharmaceutical industry, where partnerships are crucial for achieving innovation and meeting regulatory requirements efficiently.
In addition to the successful launch of MEIYOUHENG®, the event at BioDlink’s headquarters in Suzhou serves as a celebration of the broader advancements in China’s biopharmaceutical ecosystem. The achievement signifies not only a win for the two companies involved but also a step forward for the industry, enhancing China’s position as a competitive player in the global biopharmaceutical market.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

